Arovella Therapeutics Ltd
ALA
Company Profile
Business description
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
Contact
84 Hotham Street
Corporate One
PrestonVIC3072
AUST: +61 398636472
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
44
Stocks News & Analysis
stocks
Margins have bottomed for ASX listed consumer goods company
Impact of tariffs have been priced in.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,988.30 | 61.40 | -0.68% |
| CAC 40 | 8,340.71 | 59.40 | -0.71% |
| DAX 40 | 24,893.58 | 246.11 | -0.98% |
| Dow JONES (US) | 51,776.78 | 64.07 | 0.12% |
| FTSE 100 | 10,428.85 | 9.00 | -0.09% |
| HKSE | 23,336.28 | 432.24 | -1.82% |
| NASDAQ | 25,703.23 | 463.38 | -1.77% |
| Nikkei 225 | 69,788.38 | 2,565.58 | -3.55% |
| NZX 50 Index | 13,435.77 | 10.28 | -0.08% |
| S&P 500 | 7,386.31 | 86.48 | -1.16% |
| S&P/ASX 200 | 8,787.00 | 48.10 | -0.54% |
| SSE Composite Index | 4,106.25 | 56.85 | -1.37% |